Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8797914 | 0.88 | CA12 (0.41) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8800410 | 0.75 | RORC (0.32) | MEN1CYP1A2MAPTKMT2A | |
| SCHEMBL3798990 | 0.71 | CYP1A2 (0.41) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL276858 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL104411 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2007380 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL276859 | 0.71 | ADORA2A (0.42) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18630046 | 0.71 | TRPA1 (0.44) | CYP1A2CYP3A4CYP2D6MAPTMAPK1 | |
| SCHEMBL288995 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5424464 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122061-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-12492195-B2 | Preparation method for and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2025-12-09 | — | — | US | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-115135644-B | Preparation method and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | 漳州片仔癀药业股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117769547-A | Preparation method of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | 上海璃道医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230339920-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYLPROPYLAMINE COMPOUND | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339920-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYLPROPYLAMINE COMPOUND | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4257196-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | The University of Hong Kong (HK) | 2023-10-11 | — | — | EP | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20040248889-A1 | Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists | GRUENENTHAL GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1412361-A1 | SUBSTITUTED 5,6,6A,11B-TETRAHYDRO-7-OXA-5-AZA-BENZO[C]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003014124-A1 | SUBSTITUTED 5,6,6A,11B-TETRAHYDRO-7-OXA-5-AZA-BENZO[C]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-02-20 | — | — | WO | disclosed |
| EP-0355827-B1 | Hydantoin derivatives | MOCHIDA PHARM CO LTD (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-RE35279-E | ALDOSE REDUCTASE INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
| US-5202339-A | Hypoglycemic, hypolipedemic agents | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| US-5004751-A | Antidiabetic agents; aldoe reductase inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| WO-1990002126-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355827-A2 | Hydantoin derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492195-B2 | Preparation method for and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | TRPC7, TRPV1, TRPC5 | MEN1 1938/4885NPC1 1103/4885CYP1A2 1568/4885 |
| US-20040248889-A1 | Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists | GRIN3A, GRIK5, GRIN2C | MEN1 3477/4885NPC1 2662/4885CYP1A2 957/4885 |
| US-20230339920-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYLPROPYLAMINE COMPOUND | TRPV1, TRPC7, TRPC4 | MEN1 2283/4885NPC1 773/4885CYP1A2 1301/4885 |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | YEATS2, YEATS4, KNTC1 | MEN1 2276/4885NPC1 1356/4885CYP1A2 4168/4885 |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE2, WEE1 | MEN1 769/4885NPC1 2261/4885CYP1A2 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.